May 21 |
Here's Why Momentum in Lipocine (LPCN) Should Keep going
|
May 9 |
Lipocine GAAP EPS of $0.66, revenue of $7.62M
|
May 9 |
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
|
May 8 |
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
|
May 1 |
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
|
Apr 11 |
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
|
Mar 28 |
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
|
Mar 25 |
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
|
Mar 7 |
Lipocine GAAP EPS of -$3.14
|
Mar 7 |
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
|